Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Verona Pharma Fundamentals

Company Name n/a Last Updated 19 Oct 2020
Industry Health Care Sector Biotechnology
Shares in Issue (m) 414.55 Market Cap (£m) 217.64
PE Ratio -1.73 Div per Share () 0.00
Div Yield 0.00 Div Cover 0.00
EPS -30.30 EPS Growth (%) -60.32
PEG 0.03 DPS Growth (%) n/a
Debt Ratio 4.66 Debt Equity Ratio 0.15
Net Gearing -25.84 Gross Gearing 24.97
Asset Equity Ratio 1.33 Cash Equity Ratio 67.72
Quick Ratio 4.26 Current Ratio 4.26
Price To Book Value 6.43 ROCE -110.39

Verona Pharma Dividends

Type Ex-Date Pay Date Currency Net Dividend Year Total

Verona Pharma Company Financials

Assets (£m) 2019 2018 2017
Tangible Assets 0 0 0
Intangible Assets 3 3 2
Investments 1 0 0
Total Fixed Assets 4 3 2
Stocks 0 0 0
Debtors 3 2 2
Cash & Equivalents 23 20 31
Other Assets 15 49 54
Total Assets 45 74 90
Liabilities (£m) 2019 2018 2017
Creditors within 1 year 10 10 9
Creditors after 1 year 2 1 1
Other Liabilities 0 0 0
Total Liabilities 11 11 10
Net assets 34 63 80
Equity (£m) 2019 2018 2017
Called up share capital 5 5 5
Share Premium 119 119 119
Profit / Loss -39 -24 -25
Other Equity 10 8 5
Preference & Minorities 0 0 0
Total Capital Employed 34 63 80
Ratios 2019 2018 2017
Debt Ratio 4.66 1.72 1.27
Debt-to-Equity 0.15 0.10 0.11
Net Gearing -25.84 -11.39 -24.38
Gross Gearing 24.97 15.25 10.75
Assets / Equity 1.33 1.18 1.12
Cash / Equity 67.72 31.44 39.36
EPS -30.30 -18.90 -23.40
Cash Flow (£m) 2019 2018 2017
Cash from operating activities -34 -18 -21
Cashflow before financing 4 -13 -70
Increase in Cash 4 -13 -7
Income (£m) 2019 2018 2017
Turnover 0 0 0
Cost of sales 0 0 0
Gross Profit 0 0 0
Operating Profit -41 -26 -30
Pre-Tax profit -39 -24 -25
Profit / Loss for the year 5 5 5

Verona Pharma Company Background

Sector Biotechnology
Activities Verona Pharma plc (formerly Isis Resources plc) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma's product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. Following a response from the U.S. FDA to Verona Pharma's End-of-Phase 2 briefing package, the Company plans to initiate its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) later in 2020 for nebulized ensifentrine for COPD maintenance treatment. The Company raised gross proceeds of $200 million through a private placement in July 2020 and expects the funds to support its operations and Phase 3 clinical program into 2023. Verona Pharma is currently in Phase 2 development with two additional formulations of ensifentrine for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). Ensifentrine also has potential applications in cystic fibrosis, asthma, COVID-19 and other respiratory diseases.
Latest Interim Date 14 Aug 2020
Latest Fiscal Year End Date 27 Feb 2020

Verona Pharma Directors

Appointed Director Position
2012-06-01 Sven Jan-Anders Karlsson Chief Executive Officer
2014-12-01 Dr David Raymond Ebsworth Non-Executive Chairman
2015-09-10 Dr Sven Anders Ullman Non-Executive Director
2016-09-12 Vikas Sinha Non-Executive Director
2016-07-29 Andrew Sinclair Non-Executive Director
2016-07-29 Mahendra Shah Non-Executive Director
2016-07-29 Rishi Gupta Non-Executive Director
2015-09-10 Dr Kenneth Thomas Cunningham Non-Executive Director

Verona Pharma Contact Details

Company Name n/a
Company Address 3 More London Riverside, London SE1 2RE.
Company Telephone +44 (0)203 283 4200
Company Website http://www.veronapharma.com/

Verona Pharma Advisors

Auditor Name UHY Hacker Young LLP
Auditor Address Quadrant House, 17 Thomas More Street, Thomas More Square, London E1W 1YW.
Auditor Website http://www.uhy-uk.com/
Auditor Telephone +44 (0)20 7216 4600
Registrar Name Computershare Investor Service
Registrar Address The Pavillions, Bridgwater Road, Bristol BS99 1XZ.
Registrar Website http://www-uk.computershare.com/
Registrar Telephone 0870 702 0010
Broker Name N+1 Singer
Broker Address One Bartholomew Lane, London EC2N 2AX.
Broker Website http://www.n1singer.com/
Broker Telephone +44 (0)20 7496 3000
Adviser Name N+1 Singer
Adviser Address One Bartholomew Lane, London EC2N 2AX.
Adviser Website http://www.n1singer.com/
Adviser Telephone +44 (0)20 7496 3000
Solicitor Name Taylor Wessing
Solicitor Address 5 New Street Square, London EC4A 3TW.
Solicitor Website http://www.taylorwessing.com/
Solicitor Telephone +44 (0)20 7300 7000
Stockbroker Name n/a
Stockbroker Address n/a
Stockbroker Website n/a
Stockbroker Telephone n/a